Video Series

Experts in behavioral health discuss therapeutic options for TRD and considerations for defining value.

Jay Weaver, PharmD, MPH, and Muhamed Baljević, MD, FACP, discuss how RWE can affect the management of MM.

Dr Richter relays some of the differences between real-world evidence (RWE) and RCT data, as well as how they can work together when determining therapy.

Dr Samuel Nordberg and Carrie Jardine discuss barriers to access to care for patients with TRD and provide insight on addressing these concerns to achieve optimal care.

Dr. Samuel Nordberg discusses methods for identifying patients in need of an alternative therapy for TRD at the health system level.

Dr Baljević explain some of the limitations physicians can come across with applying randomized clinical trial (RCT) data to MM treatment.

A panel of experts elaborate on the decision support tools that are utilized by physicians to give patients high-value regimens.

The panel discusses the data used to evaluate healthcare resources for MM therapy, as well as economic burden.

Dr Beveridge provides a payer’s perspective on the available regimens for MM treatment.

Joshua Richter, MD, and Roy Beveridge, MD, explain the role triplet regimens play in MM treatment and how physician decision-making has been impacted since the NCCN guidelines have expanded the list of acceptable first- and second-line treatment options.

Muhamed Baljević, MD, FACP, provides a background of multiple myeloma (MM) within the past five years and the main treatment options.

Kashyap Patel, MD, and Jason Starr, DO, explain the potential changes providers might see in the future for MRD.

Jason Starr, DO, discusses the INSPIRE and IMvigor011 studies that focused on the use of ctDNA in MRD.

Our experts tell us how we can support the availability of MRD for more patients.

Dr Patel describes the importance of MRD in value-based care models.

Kashyap Patel, MD, and Jason Starr, DO, explain the various potential uses for MRD results and how they guide treatment decisions.

Jason Starr, DO, discusses MRD assessments, including: when they are done, where the testing takes place, and how often they are recommended.

The panel closes the program with giving their final thoughts on individualizing therapies for plaque psoriasis and metabolic syndrome in specific patient subpopulations.

Drs Lebwohl and Groves list support services to help with patient adherence.

Bhavesh Shah, PharmD, explains how lower volume agents can be beneficial when treating plaque psoriasis and metabolic syndrome.

Robert Groves, MD, and Bhavesh Shah, PharmD, comment on the role real-world evidence plays in creating cost/value analyses for psoriasis and metabolic syndrome.

Dr Groves discusses the impact of population health knowledge in patients with metabolic syndrome.

Dr Lebwohl explains how he can recognize who will respond early to psoriasis treatments and who won’t respond at all.

Bhavesh Shah, PharmD, elaborates on switching biologics in psoriasis treatment.

Drs Lebwohl and Groves comment on what they factor in when deciding to switch agents and provide targeted treatments for psoriasis and metabolic syndrome.

Ryan Haumschild, PharmD, MS, MBA discusses the potential to lower total costs through care pathways designed to start patients with plaque psoriasis and metabolic syndrome on treatments that have shown to have better overall outcomes, such as tildrakizumab.

Jason Starr, DO, explains circulating tumor DNA’s (ctDNA) role in oncology and its role in MRD.

Jason Starr, DO, provides an overview of molecular residual disease (MRD) in the hematological and oncological treatment landscapes.

Mark Lebwohl, MD, details how he extrapolates clinical data in his decision-making when trying to treat patients with psoriasis.

Drs Groves and Lebwohl discuss payer considerations for ensuring treatment with the appropriate agent for patients with psoriasis and metabolic syndrome.